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Background and Aims: The mortality rate from disseminated intravascular coagulation (DIC) is higher in patients with lung cancer than in non-lung cancer patients.Moreover, the prevalence of DIC varies among the pathologic types of lung cancer. This study analyzed the relationship between blood coagulation factors and pathologic types of lung cancer, with the aim of preventing DIC in lung cancer.
Methods: Twenty-six patients with progressive, inoperable stage IIB or higher lung cancer (20 men, 6 women; mean age 71 years; 11 Adeno, 10 squamous cell carcinoma, and 5 small cell carcinoma) and five healthy volunteers without respiratory disease (3 men, 2 women; mean age 72 years) were enrolled in the study. Blood samples were collected at lung cancer diagnosis, before treatment.
Results: White blood cell count, platelet count, serum C-reactive protein, fibrin/fibrinogen degradation products, fibrinogen, thrombinantithrombin complex, and D-dimer levels differed significantly between lung cancer patients and the control group, but not among the pathologic types of lung cancer. Thrombomodulin levels were significantly higher in patients with Adeno and squamous cell carcinoma than in those with small cell carcinoma (P < 0.05 and P < 0.01, respectively). Antithrombin levels were significantly lower in patients with squamous cell carcinoma than in those with Adeno (P < 0.05). and 04/2014 were treated in our institute. Among these patient, 609 cases were stage III disease (AJCC 7th. ed). The choice of first-line therapy, tumor size, smoking status, EGFR mutation and other clinical factors were collected for analyzing the influence of the survival.
Results: The 418 patients (68.6%) were male and 191 (31.4%) patient are females. 411 patients had never received curable surgery. In these inoperable patients, 219 (53.2%) patients had received first line chemotherapy, 135 (32.8%) patients had received CCRT or sequential chemoradiotherapy. Besides, 57 patients (13.9%) took oral TKI as first line therapy. The median PFS in CT, Combined, Target groups were 5.6, 7.9, 17.3 months respectively ( P < 0.001). The OS in these groups were 14.7, 14.8, 36.4 months respectively (P < 0.001). In this retrospective analysis, sequential chemoradiotherapy had longer PFS ( 9.5 vs 5.83 months, P = 0005) than CCRT and had trends of longer OS (20.1 vs 12.1 months , P = 0.098). 
Conclusion

